Skip to main content

Table 4 ACMG-AMP classification of PTS gene variants reported among Iranian population

From: In silico analysis and the pathogenicity classification of PTS gene variants among Iranian population

Row

Variant

ACMG-AMP criteria

Classification

Reference/s used

1

c.70C>G (p.His24Asp)

PM2, PP2, PP3, PP4

VUS

Khani et al., 2021

2

c.155A>G (p.Asn52Ser)

PM3_VS, PM2, PP2, PP3, PP4

P

Khatami et al., 2017 & Khani et al., 2021 & Almannai et al., 2019 & Leuzzi et al., 2010 & Hong et al., 2015 & Wang et al., 2019 & Gundorova et al., 2021 & Han et al., 2015

3

c.200C>T (p.Thr67Met)

PM3_VS, PM2, PP2, PP3, PP4

P

Oppliger et al., 1997 & Khani et al., 2021 & Liu et al., 2001 & Pangkanon et al., 2006 & Chaiyasap et al., 2017

4

c.259C>T (p.Pro87Ser)

PM3_VS, PM2, PP2, PP3, PP4

P

Khatami et al., 2017 & Imamura et al., 1999 & Cao et al., 2014 & Wang et al., 2019 & Liu et al., 2001 & Gundorova et al., 2021 & Gu et al., 2014 & Han et al., 2015

5

c.281A>T (p.Asp94Val)

PM2, PM3_Su, PP2, PP3, PP4

LP

Khatami et al., 2017 & Khani et al., 2021

6

c.286G>A (p.Asp96Asn)

PM3_VS, PS3_Su, PM2, PP2, PP4

P

Khani et al., 2021 & Liu et al., 2001 & Han et al., 2015 & Cao et al., 2014 & Imamura et al., 1999

7

c.293C>T (p.Pro98Leu)

PM3_Su, PM2, PP2, PP3, PP4

LP

Khani et al., 2021 & Chiu et al., 2012

8

c.297C>A (p.Tyr99Ter)

PVS1, PM2, PM3, PP4

P

Khatami et al., 2017

9

c.317C>T (p.Thr106Met)

PM3_VS, PM2, PP2, PP3, PP4

P

Khatami et al., 2017 & Khani et al., 2021 & Leuzzi et al., 2010 & Hong et al., 2015 & Gundorova et al., 2021 & Han et al., 2015 & Manti et al., 2020

10

c.331G>A (p.Ala111Thr)

PM2, PM3_Su, PP2, PP3, PP4

LP

Khatami et al., 2017 & Khani et al., 2021 & Chiu et al., 2012 & Li et al., 2018

11

c.351C>A (p.Asn117Lys)

PM2, PM3_Su, PP2, PP4

VUS

Khatami et al., 2017 & Khani et al., 2021

12

c.367C>T (p.Pro123Ser)

PM2, PM3_Su, PP2, PP3, PP4

LP

Khani et al., 2021 & Almannai et al., 2019

13

c.373G>A (p.Gly125Arg)

PM2, PM3, PP2, PP3, PP4

LP

Khani et al., 2021

14

c.400G>A (p.Glu134Lys)

PM3_S, PM2, PP2, PP3, PP4

LP

Khatami et al., 2017 & Gundorova et al., 2021 & Almannai et al., 2019

15

c.407A>T (p.Asp136Val)

PM3_VS, PM2, PS3_Su, PP2, PP4

P

Khani et al., 2021 & Dudešek et al., 2001 & Żekanowski et al., 1998 & Oppliger et al., 1997

16

c.412A>C (p.Asn138His)

PM2, PM3_Su, PP2, PP3, PP4

LP

Khani et al., 2021

17

c.84-3C>G

PM3_VS, PS3_Su, PM2, PP4

P

Khatami et al., 2017 & Khani et al., 2021 & Romstad et al., 1999 & Gundorova et al., 2021 & Manti et al., 2020, Oppliger et al., 1997

18

c.163+2T>C

PVS1, PM2, PP4

P

Khatami et al., 2017

19

c.164-1G>C

PVS1, PM2, PP4

P

Manti et al., 2020

20

c.315-1G>A

PVS1, PM2, PM3, PP4

P

Gundorova et al., 2021

21–54

The ACMG-AMP classification of other variants were as follows:

c.83+84A>T, c.84-97_84-96del, c.84-7dup, c.84-7del, c.163+14T>C, c.164-97T>C, c.187-81A>G, and c.243+94T>A (all with BA1, BS2, BP4 criteria and benign classification) & c.186+184dup, c.187-52G>A, c.243+154C>T (all with BS1, BS2, BP4 criteria and benign classification) & c.163+92C>T, c.163+136G>T, c.164-92C>G, c.164-36A>G, c.186+122T>C, c.186+132G>T, c.243+119G>A, c.243+136A>G, and c.315-94C>T (all with PM2, BP4 criteria and VUS classification) & c.84-6G>T, c.84-5G>T, c.84-3C>T, c.186+166A>G, c.186+169G>C, c.243+11G>A, and c.243+97C>T (all with BP4 criterion and VUS classification) & c.312G>A (p.Val104=), c.318G>A (p.Thr106=), and c.420G>T (p.Val140=) (all with BP7 criterion and VUS classification) & c.314+20G>A (with BS2, BP4 criteria and likely benign classification) & c.405T>C (p.Thr135=) (with BA1, BS2, BP7 criteria and benign classification) & c.-19C>T and c.*16T>C (both without any criteria and with VUS classification)

  1. VUS: variant of uncertain significance, P: pathogenic, LP: likely pathogenic